cells

Colorectal Clinical Trials

Colorectal Cancer (ARC-3)

Overview

A Phase 1/1b open-label dose-escalation and dose-expansion trial to evaluate the safety, tolerability, PK, PD, and clinical activity of etrumadenant + mFOLFOX in participants with gastroesophageal cancer or colorectal cancer.

Key Eligibility Criteria

  • They have histologically confirmed colorectal cancer that is metastatic, advanced, or recurrent with progression
  • Participants for whom mFOLFOX is considered appropriate therapy
  • Oxaliplatin-based therapy was not the most recent regimen prior to enrolling in the trial, except if prior oxaliplatin-based therapy was received in the adjuvant setting and completed ≥ 6 months prior to trial enrollment

ARC-3 Clinical Trial Locations

clinicaltrials.gov

arrow

Colorectal Cancer (ARC-9)

Overview

A randomized Phase 1b/2, open-label, multi-center platform study to evaluate the efficacy of etrumadenant (AB928)-based combinations in patients with metastatic colorectal cancer.

Key Eligibility Criteria

  • Histologically confirmed metastatic colorectal adenocarcinoma
  • Inclusion Criteria for Cohort A:
    • Disease progression following not more than one prior line of treatment for mCRC that consisted of oxaliplatin or irinotecan containing chemotherapy in combination with a biologic agent
  • Inclusion Criteria for Cohort B:
    • Disease progression during or following not more than two separate lines of treatment for mCRC that consisted of oxaliplatin, and irinotecan containing chemotherapy in combination with a biologic agent
  • Inclusion Criteria for Cohort C:
    • Disease progression during or following more than three separate lines of treatment for mCRC

ARC-9 Clinical Trial Locations

clinicaltrials.gov

arrow